

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION N	10.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/736,289		12/12/2003	Wenge Zhong	A-830	4535
21069	7590	08/21/2006		EXAMINER	
AMGEN			DAVIS, ZINNA NORTHINGTON		
MAIL STOP 28-2-C ONE AMGEN CENTER DRIVE			ART UNIT	PAPER NUMBER	
THOUSAND OAKS, CA 91320-1799				1625	
	·			DATE MAILED: 08/21/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
		10/736,289	ZHONG ET AL.				
	Office Action Summary	Examiner	Art Unit				
		Zinna Northington Davis	1625				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status							
1)⊠	Responsive to communication(s) filed on 14 M	March 2006 .					
2a)□		is action is non-final.					
3)□	, <del>-</del>						
Disposition of Claims							
4)⊠ Claim(s) <u>1-34</u> is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5)	Claim(s) is/are allowed.						
6)⊠	6)⊠ Claim(s) <u>1-34</u> is/are rejected.						
7)	Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement.  Application Papers							
	The specification is objected to by the Examine	r.					
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) All b) Some * c) None of:							
	1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents have been received in Application No						
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>							
14)⊠ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) The translation of the foreign language provisional application has been received.  15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
1)  Notice 2)  Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s) _	5) Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152)				

Application/Control Number: 10/736,289 Page 2

Art Unit: 1625

## **DETAILED ACTION**

- 1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under *Ex Parte Quayle*, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on March 14, 2006 has been entered.
- 2. The indicated allowability of the claims is withdrawn in view of the prior art references. The rejections based on the cited reference(s) follow.
- 3. Applicant is reminded that the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(h).
- 4. The following is a quotation of the second paragraph of 35 U.S.C. 112:
  The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
- 5. Claims 1-33 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
- A. At claims 2-8, 10, 12, 13, 15-26, and 28-33, it is suggested that the phrase" A Compound" should be amended to read in favor of "A compound".

Application/Control Number: 10/736,289

Art Unit: 1625

- B. At claims 1-28, 32, and 33, it is suggested that the phrase " and pharmaceutically acceptable salts should be amended to read in favor of "or a pharmaceutically acceptable salt".
- 6. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) The invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-4, 8,14-17, 24, 25, and 34 rejected under 35 U.S.C. 102(b) as being clearly anticipated by Chihiro et al (Reference A2, cited by Applicants on April 5, 2004).

The instantly claimed compound is disclosed. At Table 8, page 107, see the compound of Example 8. The claims are fully met when R<sup>1</sup> and R<sup>2</sup> together form at ring; W is thiazolyl; and Q is substituted aryl.

7. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) The invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000.

Application/Control Number: 10/736,289

**Art Unit: 1625** 

Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Claims 1, 8, 14, 17, 24, 25, and 34 are rejected under 35 U.S.C. 102(e) as being clearly anticipated by Prieple et al (Reference 1, cited by Applicants on March 14, 2006).

The instantly claimed compound is disclosed. At page 14, 1st column, see Example 24. The claims are fully met when  $R^1$  and  $R^2$  together form at ring; W is thiazolyl; and Q is  $N^R5C(O)R^5$ ;  $R^5$  is H when attached to the N-atom;  $R^5$  is substituted aryl when attached to C(O);  $R^5$  is  $-CO_2R^5$  is a radical substituted off phenyl ring;  $R^5$  is hydrogen when attached to -O. See the compound depicted below:

8. The Information Disclosure Statement filed March 14, 2006 has been considered.

The Doroshenko et al compounds are depicted below:

Art Unit: 1625

The difference between the prior art compounds and the instantly claimed compounds is the Q group. For the prior art compounds, Q is unsubstituted aryl. For the instantly claimed compounds Q is substituted aryl. There is no teaching nor suggested to modify the Doroshenko et al. compounds to derive those instantly claimed. Accordingly, no rejections are made over this prior art reference.

- 9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Zinna N. Davis whose telephone number is 571-272-0682.
- 10. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
- 11. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Źil⁄na Northington Davis Primary Examiner

Art Unit 1625